138 related articles for article (PubMed ID: 37466368)
1. Trypanosoma brucei Invariant Surface gp65 Inhibits the Alternative Pathway of Complement by Accelerating C3b Degradation.
Lorentzen J; Olesen HG; Hansen AG; Thiel S; Birkelund S; Andersen CBF; Andersen GR
J Immunol; 2023 Sep; 211(5):862-873. PubMed ID: 37466368
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of complement inhibition by the trypanosome receptor ISG65.
Cook AD; Carrington M; Higgins MK
Elife; 2024 Apr; 12():. PubMed ID: 38655765
[TBL] [Abstract][Full Text] [Related]
3. Cryo-EM structures of Trypanosoma brucei gambiense ISG65 with human complement C3 and C3b and their roles in alternative pathway restriction.
Sülzen H; Began J; Dhillon A; Kereïche S; Pompach P; Votrubova J; Zahedifard F; Šubrtova A; Šafner M; Hubalek M; Thompson M; Zoltner M; Zoll S
Nat Commun; 2023 Apr; 14(1):2403. PubMed ID: 37105991
[TBL] [Abstract][Full Text] [Related]
4. Preimplantation embryos cooperate with oviductal cells to produce embryotrophic inactivated complement-3b.
Tse PK; Lee YL; Chow WN; Luk JM; Lee KF; Yeung WS
Endocrinology; 2008 Mar; 149(3):1268-76. PubMed ID: 18039777
[TBL] [Abstract][Full Text] [Related]
5. Invariant surface glycoprotein 65 of Trypanosoma brucei is a complement C3 receptor.
Macleod OJS; Cook AD; Webb H; Crow M; Burns R; Redpath M; Seisenberger S; Trevor CE; Peacock L; Schwede A; Kimblin N; Francisco AF; Pepperl J; Rust S; Voorheis P; Gibson W; Taylor MC; Higgins MK; Carrington M
Nat Commun; 2022 Aug; 13(1):5085. PubMed ID: 36038546
[TBL] [Abstract][Full Text] [Related]
6. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
Sahu A; Isaacs SN; Soulika AM; Lambris JD
J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
[TBL] [Abstract][Full Text] [Related]
7. Cell-surface regulation of the human alternative pathway of complement. Sheep but not rabbit erythrocytes express factor I-dependent cofactor activity.
Ezzell JL; Parker CJ
Scand J Immunol; 1992 Jul; 36(1):79-87. PubMed ID: 1535452
[TBL] [Abstract][Full Text] [Related]
8. Deposition of C3b and iC3b onto particulate activators of the human complement system. Quantitation with monoclonal antibodies to human C3.
Newman SL; Mikus LK
J Exp Med; 1985 Jun; 161(6):1414-31. PubMed ID: 2409200
[TBL] [Abstract][Full Text] [Related]
9. Restriction of the alternative pathway of human complement by intact Trypanosoma brucei subsp. gambiense.
Devine DV; Falk RJ; Balber AE
Infect Immun; 1986 Apr; 52(1):223-9. PubMed ID: 3633873
[TBL] [Abstract][Full Text] [Related]
10. Structure of C3b in complex with CRIg gives insights into regulation of complement activation.
Wiesmann C; Katschke KJ; Yin J; Helmy KY; Steffek M; Fairbrother WJ; McCallum SA; Embuscado L; DeForge L; Hass PE; van Lookeren Campagne M
Nature; 2006 Nov; 444(7116):217-20. PubMed ID: 17051150
[TBL] [Abstract][Full Text] [Related]
11. The Sez6 Family Inhibits Complement by Facilitating Factor I Cleavage of C3b and Accelerating the Decay of C3 Convertases.
Qiu WQ; Luo S; Ma SA; Saminathan P; Li H; Gunnersen JM; Gelbard HA; Hammond JW
Front Immunol; 2021; 12():607641. PubMed ID: 33936031
[TBL] [Abstract][Full Text] [Related]
12. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of resistance to lysis by the alternative complement pathway in Trypanosoma cruzi trypomastigotes: effect of specific monoclonal antibody.
Schenkman S; Güther ML; Yoshida N
J Immunol; 1986 Sep; 137(5):1623-8. PubMed ID: 2943798
[TBL] [Abstract][Full Text] [Related]
14. Structure-Guided Engineering of a Complement Component C3-Binding Nanobody Improves Specificity and Adds Cofactor Activity.
Pedersen H; Jensen RK; Hansen AG; Petersen SV; Thiel S; Laursen NS; Andersen GR
Front Immunol; 2022; 13():872536. PubMed ID: 35935935
[TBL] [Abstract][Full Text] [Related]
15. Autoantibodies Against C3b-Functional Consequences and Disease Relevance.
Vasilev VV; Radanova M; Lazarov VJ; Dragon-Durey MA; Fremeaux-Bacchi V; Roumenina LT
Front Immunol; 2019; 10():64. PubMed ID: 30761135
[TBL] [Abstract][Full Text] [Related]
16. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
17. Differences between the binding sites of the complement regulatory proteins DAF, CR1, and factor H on C3 convertases.
Pangburn MK
J Immunol; 1986 Mar; 136(6):2216-21. PubMed ID: 2419425
[TBL] [Abstract][Full Text] [Related]
18. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
19. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
Waldo FB; Forristal J; Beischel L; West CD
J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
[TBL] [Abstract][Full Text] [Related]
20. Factor H-related protein 4 activates complement by serving as a platform for the assembly of alternative pathway C3 convertase via its interaction with C3b protein.
Hebecker M; Józsi M
J Biol Chem; 2012 Jun; 287(23):19528-36. PubMed ID: 22518841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
